HIV Reverse Transcriptase

Antiviral Agents
Impact of Novel Human Immunodeficiency Virus Type 1 Reverse Transcriptase Mutations P119S and T165A on 4′-Ethynylthymidine Analog Resistance Profile
Guangwei Yang, Elijah Paintsil, Ginger E. Dutschman, Susan P. Grill, Chuan-Jen Wang, Jimin Wang, Hiromichi Tanaka, Takayuki Hamasaki, Masanori Baba, Yung-Chi Cheng
Antiviral Agents
Human Immunodeficiency Virus Type 1 Recombinant Reverse Transcriptase Enzymes Containing the G190A and Y181C Resistance Mutations Remain Sensitive to Etravirine
Hongtao Xu, Yudong Quan, Bluma G. Brenner, Tamara Bar-Magen, Maureen Oliveira, Susan M. Schader, Mark A. Wainberg
Antiviral Agents
Antiviral Activity of MK-4965, a Novel Nonnucleoside Reverse Transcriptase Inhibitor
Ming-Tain Lai, Vandna Munshi, Sinoeun Touch, Robert M. Tynebor, Thomas J. Tucker, Philip M. McKenna, Theresa M. Williams, Daniel J. DiStefano, Daria J. Hazuda, Michael D. Miller
Antiviral Agents
Human Immunodeficiency Virus Type 1 Isolates with the Reverse Transcriptase (RT) Mutation Q145M Retain Nucleoside and Nonnucleoside RT Inhibitor Susceptibility
Vici Varghese, Yumi Mitsuya, Rajin Shahriar, Michael H. Bachmann, W. Jeffrey Fessel, Ron M. Kagan, Robert W. Shafer
Antiviral Agents
Single-Dose Escalation and Multiple-Dose Safety, Tolerability, and Pharmacokinetics of IDX899, a Candidate Human Immunodeficiency Virus Type 1 Nonnucleoside Reverse Transcriptase Inhibitor, in Healthy Subjects
Xiao-Jian Zhou, Keith Pietropaolo, David Damphousse, Bruce Belanger, Jie Chen, John Sullivan-Bólyai, Douglas Mayers
Antiviral Agents
Apricitabine Does Not Select Additional Drug Resistance Mutations in Tissue Culture in Human Immunodeficiency Virus Type 1 Variants Containing K65R, M184V, or M184V plus Thymidine Analogue Mutations
Maureen Oliveira, Daniela Moisi, Bonnie Spira, Susan Cox, Bluma G. Brenner, Mark A. Wainberg
Antiviral Agents
Detection of Human Immunodeficiency Virus (HIV) Type 1 M184V and K103N Minority Variants in Patients with Primary HIV Infection
Thomas A. Toni, Eugene L. Asahchop, Daniela Moisi, Michel Ntemgwa, Maureen Oliveira, Bernard Masquelier, Bluma G. Brenner, Mark A. Wainberg
Antiviral Agents
Novel Nucleotide Human Immunodeficiency Virus Reverse Transcriptase Inhibitor GS-9148 with a Low Nephrotoxic Potential: Characterization of Renal Transport and Accumulation
Tomas Cihlar, Genevieve LaFlamme, Robyn Fisher, Anne C. Carey, Jennifer E. Vela, Richard Mackman, Adrian S. Ray
Pharmacology
Development of an Optimized Dose for Coformulation of Zidovudine with Drugs That Select for the K65R Mutation Using a Population Pharmacokinetic and Enzyme Kinetic Simulation Model
Selwyn J. Hurwitz, Ghazia Asif, Nancy M. Kivel, Raymond F. Schinazi
Antiviral Agents
Mechanism of Inhibition of Human Immunodeficiency Virus Type 1 Reverse Transcriptase by a Stavudine Analogue, 4′-Ethynyl Stavudine Triphosphate
Guangwei Yang, Jimin Wang, Yao Cheng, Ginger E. Dutschman, Hiromichi Tanaka, Masanori Baba, Yung-Chi Cheng

Pages